ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Estimation of Plasma Meropenem Concentrations in Patients with Severe Infections Using Ultraviolet and Visible Range Spectrophotometry: A Pilot Study.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04282785 (Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Point-of-care Monitoring of Antibiotic Concentration in Blood With UV-VIS Absorption Spectroscopy
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
BACKGROUND AND
objectiveAchieving adequate concentrations of beta-lactam antibiotics in patients with severe infections is challenging, and therefore therapeutic drug monitoring (TDM) would be optimal for guiding beta-lactam dosing, but is often limited by availability. UV/VIS spectrophotometry can quantify drug levels in saline, and if those levels truly reflect plasma concentrations, it could enable bedside TDM. We set out to determine whether ultraviolet and visible light range (UV/VIS) spectrophotometry can accurately estimate plasma meropenem concentrations in patients with severe infections compared with liquid chromatography with tandem mass spectrometry (LC‑MS/MS).
methodsBlood samples were collected before the first meropenem dose, or if not possible, at least 24 h after the last meropenem dose (baseline), and 2 h after administration. Total plasma concentrations were determined by LC‑MS/MS.
resultsA total of 36 patients and 59 samples were included. The correlation between absorbance and meropenem concentrations was r
conclusionsIn patients with severe infections, UV/VIS spectrophotometric estimation of plasma meropenem concentrations currently lacks the precision to estimate meropenem measured by LC‑MS/MS.
trial registrationNCT04282785, 25/02/2020.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.